[ad_1]
NEW YORK, May 24, 2022 /PRNewswire/ — Biotech Acquisition Company (NASDAQ:BIOT) (“BAC“), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, today announced that it has made a submission to the United States Securities and Exchange Commission (“SEC“) of a prospectus supplement containing information supplements and updates to the information contained in the proxy statement/prospectus dated May 9, 2022included in Amendment No. 4 to the registration statement on Form S-4 (File No. 333-263577), relating to its previously announced proposed business combination with Blade Therapeutics, Inc. (“Blade“), a biopharmaceutical company based in South San Francisco, CA.
About Biotech Acquisition Company
Biotech Acquisition Company raised $230 million in its initial public offering in January 2021. The Class A ordinary shares and warrants of BAC trade on the Nasdaq Capital Market under the symbols “BIOT” and “BIOTW,” respectively. BAC is a blank check company, incorporated as a Cayman Islands exempted company, formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or other similar business combination with one or more businesses. BAC believes that a business combination with a company focused on the healthcare sector will complement the background and expertise of SPRIM Global Investments, a global investment firm in the life sciences and healthcare industries, which is an affiliate of BAC and of several members of the management team behind BAC. BAC is led by Dr. Michael Shleiferits CEO and chairman.
About Blade Therapeutics
Blade Therapeutics, Inc. is a biopharmaceutical company focused on developing cutting-edge treatments for debilitating, incurable fibrotic and neurodegenerative diseases that impact millions of people worldwide. The company has deep expertise in novel biological pathways – including autotaxin / LPA and calpain biology – that are foundational to cell- and tissue-damage responses resulting from protein deposition or aggregation associated with fibrotic and neurodegenerative diseases. Blade expects to advance a differentiated pipeline of oral, small-molecule therapies that include a non-competitive autotaxin inhibitor and inhibitors of dimeric calpains designed for potential treatment of lung, liver and cardiac fibrosis or neurodegenerative diseases. The company’s focused approach offers the potential to produce disease-modifying, life-saving therapies. Visit www.blademed.com for more information and follow Blade on LinkedIn.
Additional Information and Where to Find It
This press release relates to a proposed business combination between BAC and Blade (the “Transaction”). This press release does not constitute an offer to sell or exchange, or the solicitation of an offer to buy or exchange, any securities, nor shall there be be any sale of securities in any jurisdiction in which such offer, sale or exchange would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. In connection with the Transaction, BAC has publicly filed a registration statement on Form S- 4 with the US Securities and Exchange Commission (the “SEC”), which includes a preliminary proxy statement/prospectus. The registration statement has been declared effective by the SEC on May 9, 2022and BAC …
Full story available on Benzinga.com
[ad_2]
Source link
